Probiotic Treatment for Depression in Parkinson's Disease (NCT05568498)
📖 Wiki Page
clinical1192 wordssynced 2026-04-02
Overview
This clinical trial investigates whether probiotic supplementation can improve depression symptoms in Parkinson's disease patients. The study targets the gut-brain axis as a modifiable pathway for neuropsychiatric symptoms in PD. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients, and is often undertreated due to the complexity of managing depression alongside motor symptoms and dopaminergic medications.
The gut-brain axis is increasingly recognized as a key player in PD pathogenesis[@braak2006][@perez2021]. This bidirectional communication system involves neural, endocrine, immune, and metabolic pathways connecting the gastrointestinal tract with the central nervous system. In PD, pathological alpha-synuclein aggregates thought to originate in the gut and propagate via the vagus nerve to the brain, representing one of the earliest events in disease development[@bjorklund2020].
Key aspects of gut-brain axis involvement in PD include:
...
Overview
This clinical trial investigates whether probiotic supplementation can improve depression symptoms in Parkinson's disease patients. The study targets the gut-brain axis as a modifiable pathway for neuropsychiatric symptoms in PD. Depression is one of the most common non-motor symptoms in PD, affecting up to 50% of patients, and is often undertreated due to the complexity of managing depression alongside motor symptoms and dopaminergic medications.
The gut-brain axis is increasingly recognized as a key player in PD pathogenesis[@braak2006][@perez2021]. This bidirectional communication system involves neural, endocrine, immune, and metabolic pathways connecting the gastrointestinal tract with the central nervous system. In PD, pathological alpha-synuclein aggregates thought to originate in the gut and propagate via the vagus nerve to the brain, representing one of the earliest events in disease development[@bjorklund2020].
Key aspects of gut-brain axis involvement in PD include:
α-Synuclein propagation: Gut vagus nerve may transmit α-synuclein to brain[@braak2006]
Neuroinflammation: Gut-derived inflammatory signals cross the blood-brain barrier
Microbiota alterations: PD patients show distinct gut microbiome signatures[@chen2018]
Leaky gut: Increased intestinal permeability allows bacterial products to enter circulation
SCFA deficiency: Short-chain fatty acid production is reduced in PD patients
Depression in PD
Depression affects up to 50% of PD patients and represents one of the most disabling non-motor symptoms[@perez2021]:
Prevalence: Often precedes motor symptoms by years
Pathophysiology: Linked to neurotransmitter changes (dopamine, serotonin, norepinephrine)
Gut connection: Associated with gut dysfunction and microbiome alterations
Treatment challenges: Standard antidepressants have limited efficacy and can worsen motor symptoms
Impact: Significantly reduces quality of life and treatment adherence
The monoamine hypothesis of depression suggests that dysregulation of serotonin, norepinephrine, and dopamine pathways contributes to depressive symptoms. In PD, dopaminergic neuron loss directly impacts these pathways, creating a unique form of depression that may require targeted interventions beyond traditional antidepressants.
Probiotic Rationale
Probiotics may help through multiple mechanisms[@Sampson2016][@wallace2017][@sandhu2021]:
Reducing gut inflammation: Modulating immune responses and decreasing pro-inflammatory cytokines
Modulating neurotransmitter production: Certain bacterial strains produce neurotransmitters or precursors (GABA, serotonin precursors)
Improving gut barrier integrity: Strengthening tight junctions to reduce "leaky gut"
Reducing α-synuclein aggregation: Through anti-inflammatory effects and SCFA production
Producing short-chain fatty acids: Butyrate, propionate, and acetate have neuroprotective effects
Competing with pathogens: Reducing abundance of pro-inflammatory gut bacteria
The specific strains in this trial (Lactobacillus and Bifidobacterium) have been selected based on preclinical evidence showing benefits in alpha-synuclein models and human studies demonstrating safety in PD populations.
Trial Design
Study Population
Inclusion Criteria
Parkinson's disease diagnosis (UK Brain Bank criteria)